Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 3, pp 355–363

Galectin-3 in urine of cancer patients: stage and tissue specificity

  • Kiruthika Balasubramanian
  • Raghavendra Vasudevamurthy
  • Sathisha Upparahalli Venkateshaiah
  • Anil Thomas
  • A. Vishweshwara
  • Shylaja Mallaiah Dharmesh
Original Paper
  • 199 Downloads

Abstract

Purpose

Galectin-3 has been implicated in advanced stage of cancer disease. In the current study we examined the possibility of urinary galectin-3 levels to stage cancer disease and to follow up therapy.

Experimental design

Urine was collected from all types of cancer patients at different stages including patients undergoing radio/chemotherapy. Galectin-3 level was determined by anti-galectin-3 based ELISA and agglutination assays. Immunoblotting and purification on lactosyl affinity column further confirmed the presence of galectin-3.

Results

Cancer samples exhibited stage dependent expression of galectin-3 approx. ranging from 1.0 to 3.3, 4.4 to 5.4, 5.4 to 24.7, 13.1 to 31.9, 13.9 to 32.9 ng/mg C (creatinine) for stage I–V, respectively, at P ~ <0.05 level. Galectin-3 levels were decreased by approx. threefolds after 5th day of therapy.

Conclusions

Sample collection being simple and non-invasive, urinary galectin-3 may be used as a potential diagnostic tool for monitoring or follow up of the stage of cancer disease.

Keywords

Galectin-3 Hemagglutination Creatinine Metastasis Radio/chemotherapy Urine 

References

  1. Barondes S, Catronava V, Cooper D, Cummings R, Drickamer K, Feizi T et al (1994) Galectins: a family of animal β-galactoside binding lectins. Cell 76:597–598. doi:10.1016/0092-8674(94)90498-7 PubMedCrossRefGoogle Scholar
  2. Baumann M, Kappl A, Lang T, Brand K, Siegfried W, Paterok E (1990) The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney and breast cancer. Cancer Invest 8:51–56. doi:10.3109/07357909009012053 CrossRefGoogle Scholar
  3. Bresalier RS, Yan PS, Byrd JC, Lotan R, Raz A (1997) Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer Res 80:776–787Google Scholar
  4. Califice S, Castronovo V, Bracke M, Van den Brule F (2004) Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23:7527–7536. doi:10.1038/sj.onc.1207997 PubMedCrossRefGoogle Scholar
  5. Cottrell SE (2004) Molecular diagnostic applications of DNA methylation technology. Clin Biochem 37:595–604. doi:10.1016/j.clinbiochem.2004.05.010 PubMedCrossRefGoogle Scholar
  6. Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F, Wang JL (2002) Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 12:329–337. doi:10.1093/glycob/12.5.329 PubMedCrossRefGoogle Scholar
  7. Herrmann J, Truck CW, Atchison RE, Huflej ME, Poulter L, Gitt MA et al (1993) Primary structure of the soluble lactose binding lectin L-29 from rat and dog and interaction of its non-collagenous proline, glycine, tyrosine rich sequence with bacterial and tissue collagenase. J Biol Chem 208:26704–26711Google Scholar
  8. Hong SS, Kwon SW (2005) Profiling of urinary proteins by nano-high performance liquid chromatography/tandem mass spectrometry. J Liquid Chromatogr Relat Technol 28:805–822. doi:10.1081/JLC-200051465 CrossRefGoogle Scholar
  9. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S (2000) Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 6:1389–1393PubMedGoogle Scholar
  10. Kanabrocki EL, Ryan MD, Murray D, Jacobs RW, Wang J, Hurder A et al (2006) Circadian variation in multiple sclerosis of oxidative stress marker of DNA damage. A potential cancer marker? Clin Ter 157:117–122PubMedGoogle Scholar
  11. Lotz MM, Andrews CW, Korzelins CA, Lee EC, Steele GD, Jrclarke A et al (1993) Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 90:3466–3470. doi:10.1073/pnas.90.8.3466 PubMedCrossRefGoogle Scholar
  12. Lowry OH, Rosebrough NJ, Farr AL (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  13. Miyazaki J, Hokari R, Rato S, Tsuzuki Y, Kawaguchi A, Nagao S et al (2002) Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 9:1307–1312PubMedGoogle Scholar
  14. Nakahara S, Oka N, Raz A (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10:267–275. doi:10.1007/s10495-005-0801-y PubMedCrossRefGoogle Scholar
  15. Nangia-Makker P, Akahani S, Bresalier R, Raz A (2000) The role of galectin-3 in tumor metastasis. In: Lectins and pathology. Taylor and Francis Incorporation, LondonGoogle Scholar
  16. Nangia-Makker P, Hogan V, Honjo Y, Yuichiro H, Baccarini S, Tait L et al (2002) Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94:1854–1862PubMedGoogle Scholar
  17. Nowak TP, Haywood PL, Barondes SH (1976) Developmentally regulated lectin in embryonic chick muscle and a myogenic cell line. Biochem Biophys Res Commun 68:650–657. doi:10.1016/0006-291X(76)91195-5 PubMedCrossRefGoogle Scholar
  18. Oda Y, Leffler H, Sakakura Y, Kasai KI, Barondes SH (1991) Human breast carcinoma cDNA encoding a galactoside binding lectin homologous to mouse Mac-2 antigen. Gene 99:279–283. doi:10.1016/0378-1119(91)90139-3 PubMedCrossRefGoogle Scholar
  19. Rajeshwari N, Shylaja MD, Krishnappa M, Shetty HS, Mortensen CN, Mathur SB (1998) Development of ELISA for the detection of Ralstonia solanacearum in tomato: its application in seed health testing. World J Microbiol Biotechnol 14:697–704. doi:10.1023/A:1008892400077 CrossRefGoogle Scholar
  20. Raz A, Pazerini G, Carmi P (1989) Identification of the metastasis associated galactoside binding lectin as a chimeric gene product with homology to an IgE binding protein. Cancer Res 49:3489–3493PubMedGoogle Scholar
  21. Robertson MW, Albrand K, Keller D, Liu FT (1990) Human IgE binding sequence and differential recognition of IgE glycoforms. Biochemistry 29:8093–9000. doi:10.1021/bi00487a015 PubMedCrossRefGoogle Scholar
  22. Sathisha UV, Smitha J, Harish Nayaka MA, Dharmesh SM (2007) Inhibition of Galectin-3 mediated cellular interactions by pectic polysaccharides from dietary sources. Glycoconj J 24:497–507. doi:10.1007/s10719-007-9042-3 PubMedCrossRefGoogle Scholar
  23. Schoeppner HL, Raz A, Ho SB, Bresalier RS (1995) Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 75:2818–2826. doi:10.1002/1097-0142(19950615)75:12<2818::AID-CNCR2820751206>3.0.CO;2-#PubMedCrossRefGoogle Scholar
  24. Shimonishi T, Miyazaki K, Kono N, Sabit H, Tuneyama K, Harada K et al (2001) Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol 32:302–310. doi:10.1053/hupa.2001.22767 PubMedCrossRefGoogle Scholar
  25. Siemiatycki J, Dewar R, Nadon L, Gérin M (1994) Occupational risk factors for bladder cancer: results from a case-control study in Montreal, QC, Canada. Am J Epidemiol 140:1061–1080PubMedGoogle Scholar
  26. Smith RB, Smith RV, Yakatan GJ (1976) Spectrofluorometric determination of hydroflumethiazide in plasma and urine. J Pharm Sci 65:1208–1211. doi:10.1002/jps.2600650819 PubMedCrossRefGoogle Scholar
  27. Song YK, Billiar TR, Lee YJ (2002) Am J Pathol 160:1069–1075Google Scholar
  28. Takenaka Y, Fukumori T, Raz A (2002) Galectin-3 and metastasis: Special issue on Galectin. Glycoconj J 19:543–549. doi:10.1023/B:GLYC.0000014084.01324.15 CrossRefGoogle Scholar
  29. Takenaka Y, Fukumori T, Raz A (2004) Galectin-3 and metastasis. Glycoconj J 19:543–549. doi:10.1023/B:GLYC.0000014084.01324.15 PubMedCrossRefGoogle Scholar
  30. Van den Brule FA, Castronovo V (2000) Laminin binding lectins during invasion and metastasis. In: Lectins and pathology. Taylor and Francis Inc., LondonGoogle Scholar
  31. Woynarowska B, Skrincosky DM, Haag A, Sharma M, Matta K, Bernacki RJ (1994) Inhibition of lectin-mediated ovarian tumor cell adhesion by sugar analogs. J Biol Chem 269:22797–22803PubMedGoogle Scholar
  32. Yang RY, Hsu DK, Liu FT (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93:6737–6742. doi:10.1073/pnas.93.13.6737 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Kiruthika Balasubramanian
    • 1
  • Raghavendra Vasudevamurthy
    • 1
  • Sathisha Upparahalli Venkateshaiah
    • 1
  • Anil Thomas
    • 2
  • A. Vishweshwara
    • 2
  • Shylaja Mallaiah Dharmesh
    • 1
  1. 1.Department of Biochemistry and NutritionCentral Food Technological Research InstituteMysoreIndia
  2. 2.Bharath Institute of Oncology and ResearchMysoreIndia

Personalised recommendations